BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innocutis Announces Three New Prescribing Options for BIONECT™


9/19/2012 10:58:18 AM

CHARLESTON, S.C., Sept. 18, 2012 /PRNewswire/ --Innocutis is pleased to announce the introduction of three new prescribing options of Bionect® (hyaluronic acid sodium salt, 0.2%): an aqueous base 20ml spray, and aqueous base 100g cream and gel formulations.

(Photo: http://photos.prnewswire.com/prnh/20120918/PH75633 )

Available by prescription only, Bionect is formulated using a patented low molecular weight hyaluronic acid (LMWHA) and is indicated for irritations of the skin and managing redness associated with chronic conditions.

Market research has shown that patients and physicians are looking for value options when treating chronic conditions. The new Bionect 100g aqueous gel and cream formulations double the current treatment size options and are preferred by patients treating large skin areas affected by irritation and redness.

While creams and gels are commonly prescribed for topical use, they are not ideal for all areas of the body. Bionect spray 20ml is ideal for patients to use for symptoms occurring near the hairline or hair-bearing areas.

For more information or help locating a physician near you to prescribe Bionect, please visit http://bionect.com/physician-finder/

About Innocutis:

Innocutis is a pharmaceutical and medical device company specializing in the development and commercialization of therapies focused on medical treatments of dermatological conditions. We believe our focus on dermatologic conditions sets us apart as a company that understands the growing needs of the dermatology specialty. Our commitment is to be best-in-class in skin-related therapies, providing clinicians with improved solutions for the management of daily challenges experienced in their practice.

Contact:

Chuck Jenkins
Vice President of Sales & Marketing
Ph: 800-499-4468
inquiry@innocutis.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE Innocutis



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES